Javascript must be enabled to continue!
GW24-e3077 Inhibition of PICK1 has the Protective Effect on Adriamycin-induced Toxic Myocarditis
View through CrossRef
Objectives
Adriamycin (ADR) has broad-spectrum effect such as anti-tumour and antibiotic, but it is limited the application for its dose-dependent cardiac toxicity. PICK1 is the interaction protein of PKC, which has been suggested as a potential drug target against brain ischaemia, pain and cocaine addiction. Our previous study has shown that the expression of PICK1 has increased in ADR-induced toxic myocarditis. In this study, the possible protect effect of FSC231, the specifical PDZ domain inhibitor of PICK1, against ADR-induced toxic myocarditis were carried out.
Methods
An experimental ADR-induced toxic myocarditis model was induced by intraperitoneal injection of ADR (3mg/kg) one day intervals on 14 consecutive days in mice. FSC231 (0.1ml/10g, 25 μM) was administrated by intraperitoneal injection on 14 consecutive days. At the end of the experiment, mice were sacrificed and their hearts were harvested for marker enzyme, histologic and molecular biologic analysis. The expression of PKCα and PICK1 were tested by Western blot.
Results
Results showed that the myocardial fibre necrosis and the higher of lactate dehydrogenase (LDH) in myocardium were found in ADR-induced toxic myocarditis model group. Administration of FSC231 protected the injury of myocardium and reduced the content of LDH. The levels of malondialdehyde in myocardium significantly decreased in FSC231-treated group. The protein expression of PKCα and PICK1 increased in ADR-induced toxic myocarditis model group. Treatment with FSC231 did not reduced the expression of PKCα. Administration of FSC231 failed to reduced the total membrane and cytolic expression of PICK1 but inhibited the increasing membrane expression of PICK1.
Conclusions
These findings indicate that the protective effect of PICK1 on ADR-induced toxic myocarditis is involved in the alleviation of myocardium injury by reducing oxidative stress partially via inhibition of PICK1 protein. This work was supported by the National Nature Science Foundation of China (NSFC) Grant 81000576 to Fei Cai, and NSFC Grant 31000249 to JH Wang, and Foundation of Department of Education of Hubei Province Q20112801, 20112804 to Fei Cai, and Cai-Rong Li
Title: GW24-e3077 Inhibition of PICK1 has the Protective Effect on Adriamycin-induced Toxic Myocarditis
Description:
Objectives
Adriamycin (ADR) has broad-spectrum effect such as anti-tumour and antibiotic, but it is limited the application for its dose-dependent cardiac toxicity.
PICK1 is the interaction protein of PKC, which has been suggested as a potential drug target against brain ischaemia, pain and cocaine addiction.
Our previous study has shown that the expression of PICK1 has increased in ADR-induced toxic myocarditis.
In this study, the possible protect effect of FSC231, the specifical PDZ domain inhibitor of PICK1, against ADR-induced toxic myocarditis were carried out.
Methods
An experimental ADR-induced toxic myocarditis model was induced by intraperitoneal injection of ADR (3mg/kg) one day intervals on 14 consecutive days in mice.
FSC231 (0.
1ml/10g, 25 μM) was administrated by intraperitoneal injection on 14 consecutive days.
At the end of the experiment, mice were sacrificed and their hearts were harvested for marker enzyme, histologic and molecular biologic analysis.
The expression of PKCα and PICK1 were tested by Western blot.
Results
Results showed that the myocardial fibre necrosis and the higher of lactate dehydrogenase (LDH) in myocardium were found in ADR-induced toxic myocarditis model group.
Administration of FSC231 protected the injury of myocardium and reduced the content of LDH.
The levels of malondialdehyde in myocardium significantly decreased in FSC231-treated group.
The protein expression of PKCα and PICK1 increased in ADR-induced toxic myocarditis model group.
Treatment with FSC231 did not reduced the expression of PKCα.
Administration of FSC231 failed to reduced the total membrane and cytolic expression of PICK1 but inhibited the increasing membrane expression of PICK1.
Conclusions
These findings indicate that the protective effect of PICK1 on ADR-induced toxic myocarditis is involved in the alleviation of myocardium injury by reducing oxidative stress partially via inhibition of PICK1 protein.
This work was supported by the National Nature Science Foundation of China (NSFC) Grant 81000576 to Fei Cai, and NSFC Grant 31000249 to JH Wang, and Foundation of Department of Education of Hubei Province Q20112801, 20112804 to Fei Cai, and Cai-Rong Li.
Related Results
Exploring Vimentin's Role in Breast Cancer via PICK1 Alternative Polyadenylation and the miR-615-3p- PICK1 Interaction
Exploring Vimentin's Role in Breast Cancer via PICK1 Alternative Polyadenylation and the miR-615-3p- PICK1 Interaction
Abstract
Background: Breast cancer continues to be a major health issue for women worldwide, with Vimentin (VIM) identified as a crucial factor in its progression due to it...
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Background: Myocarditis and pericarditis cases following Coronavirus 2019 (COVID-19) vaccination were reported worldwide. In Thailand, COVID-19 vaccines were approved for emergency...
P1813Impact of cardiac MRI imaging on detection rates of myocarditis
P1813Impact of cardiac MRI imaging on detection rates of myocarditis
Abstract
Background
The Lake Louise Criteria for the diagnosis of myocarditis by cardiac MRI (CMR) was published in 2009 (JACC A...
Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis
Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis
Background: COVID-19 vaccines have been linked to myocarditis which in some circumstances can be fatal. This systematic review aims to investigate potential causal links between CO...
Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events w...
Effects of In Vivo Administration of Anti–B7-1/B7-2 Monoclonal Antibodies on Murine Acute Myocarditis Caused by Coxsackievirus B3
Effects of In Vivo Administration of Anti–B7-1/B7-2 Monoclonal Antibodies on Murine Acute Myocarditis Caused by Coxsackievirus B3
Abstract
—In viral myocarditis, we previously reported that antigen-specific T cells infiltrate the heart and play an important role in the pathogenesis of myocardial d...
Adverse cardiac events following mRNA COVID-19 vaccination: A systematic review and meta-analysis
Adverse cardiac events following mRNA COVID-19 vaccination: A systematic review and meta-analysis
Context: Although have been proven able to control the prevalence of coronavirus disease-19 (COVID-19), Pfizer-BioNTech and Moderna COVID-19 vaccines are reported to have possible ...
RELATIONSHIP BETWEEN MYOCARDITIS AND DENGUE
RELATIONSHIP BETWEEN MYOCARDITIS AND DENGUE
Introduction: Myocarditis, an inflammation of the heart muscle, can arise as a complication of dengue fever, a mosquito-borne disease. It is essential to adopt a multidisciplinary ...

